NeoGenomics, Inc. (NEO): Price and Financial Metrics


NeoGenomics, Inc. (NEO)

Today's Latest Price: $34.23 USD

0.05 (0.15%)

Updated Feb 18 2:03pm

Add NEO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

NEO Stock Summary

  • With a price/earnings ratio of 1,639.5, Neogenomics Inc P/E ratio is greater than that of about 99.56% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for NEO is currently 95.38, higher than 96.5% of US stocks with positive operating cash flow.
  • As for revenue growth, note that NEO's revenue has grown 41.18% over the past 12 months; that beats the revenue growth of 87.33% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Neogenomics Inc, a group of peers worth examining would be LYV, GRUB, MGM, DAKT, and LAKE.
  • NEO's SEC filings can be seen here. And to visit Neogenomics Inc's official web site, go to www.neogenomics.com.
NEO Daily Price Range
NEO 52-Week Price Range

NEO Stock Price Chart More Charts


NEO Price/Volume Stats

Current price $34.23 52-week high $34.97
Prev. close $34.18 52-week low $16.30
Day low $34.10 Volume 251,563
Day high $34.97 Avg. volume 793,716
50-day MA $30.48 Dividend yield N/A
200-day MA $24.76 Market Cap 3.57B

NeoGenomics, Inc. (NEO) Company Bio


NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.

NEO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$34.23$9.32-73%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Neogenomics Inc. To summarize, we found that Neogenomics Inc ranked in the 24st percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for NEO, they are:

  • The compound growth rate in the free cash flow of Neogenomics Inc over the past 5.51 years is 0.5%; that's higher than 80.52% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than merely 13.48% of the free cash flow producing stocks we're observing.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-73%
1%-73%
2%-73%
3%-72%
4%-72%
5%-72%

Want more companies with a valuation profile/forecast similar to that of Neogenomics Inc? See OFIX, XRAY, GKOS, WST, and DHR.


NEO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NEO Latest Social Stream


Loading social stream, please wait...

View Full NEO Social Stream

NEO Price Returns

1-mo 6.80%
3-mo 40.17%
6-mo 32.73%
1-year 94.05%
3-year 328.95%
5-year 677.95%
YTD 17.03%
2019 131.96%
2018 42.33%
2017 3.38%
2016 8.89%
2015 88.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.646 seconds.